The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder (ADHD), centanafadine, setting up a decision by 24th July.

WhiteSands Alcohol & Drug Rehab Orlando has published a new educational resource focused on treatment considerations during ...

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

News and commentary from the psychiatry world ...

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates.

Saffron is a spice that’s been used in cooking for thousands of years, but it’s popping up all over social media in recent ...

Learn how combining creatine and BCAAs can boost your workout energy, speed up muscle repair, and help you reach your fitness ...

Many species of fungus across the world produce psilocybin, a chemical with psychedelic effects in humans, but its ...

Some supplements can interact with cold and flu medications. Be aware of common interactions to promote safety and ensure proper use.

Researchers have developed a new model to study the antidepressant and anti-anxiety effects of psilocybin in mice.